Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. Sirtris Pharmaceuticals is registered under the ticker NASDAQ:SIRT . //-->. GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share. When I pointed at Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money left. Biopharmaceutical company Sirtris Pharmaceuticals Inc. said it would sell 5 million shares in its initial public offering at $9 to $11 apiece. Description. Latest Deal Amount. Under the agreement, a subsidiary of GSK will commence a cash tender offer to purchase all of the outstanding shares of Sirtris, at USD22.50 (or approx. Sirtris Pharmaceuticals Files for $60 Million IPO Published: Mar 01, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. M&A. GlaxoSmithKline is paying big in an effort to find cures for diseases of aging. Sirtris Pharmaceuticals Inc. filed with regulators on Thursday to raise up to $60 million in an initial public offering of common stock. [6] Studies published in 2009 and early 2010 by scientists from Amgen and Pfizer cast doubt on whether SIRT1 was directly activated by resveratrol and showed that the apparent activity was actually due to a fluorescent reagent used in the experiments. © 2021 TheStreet, Inc. All rights reserved. document.write("
Click here to add this page to your favorites"); CEO Christoph Westphal and the management team will continue to lead the unit. Action Alerts PLUS is a registered trademark of TheStreet, Inc. Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. $376M. GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND … Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.